Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic γ9δ2 T Cells for the Treatment of Recurrent Hematologic Tumors After Allogeneic Hematopoietic Stem Cell Transplantation

NCT05755854 is registered in ClinicalTrials.gov with Anhui Provincial Hospital as lead sponsor.

NCT NCT05755854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05755854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic γ9δ2 T Cells for the Treatment of Recurrent Hematologic Tumors After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Anhui Provincial Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
May 3, 2023
Completion date
December 31, 2025
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic diseases